HSV1 ICP4
Reaktivität: Human Herpesvirus 1 (HHV-1)
ELISA, WB, IFA
Wirt: Maus
Monoclonal
unconjugated
Applikationshinweise
Western Blotting: > 1:600. Immunofluorescence: 1+ at 1:25.600. ELISA: 0.100 at 1:26.600
Beschränkungen
Nur für Forschungszwecke einsetzbar
Konzentration
1.0 mg/ml
Buffer
Phosphate Buffered Saline pH 7.4 (no azide)
Konservierungsmittel
Azide free
Maroui, Callé, Cohen, Streichenberger, Texier, Takissian, Rousseau, Poccardi, Welsch, Corpet, Schaeffer, Labetoulle, Lomonte: "Latency Entry of Herpes Simplex Virus 1 Is Determined by the Interaction of Its Genome with the Nuclear Environment." in: PLoS pathogens, Vol. 12, Issue 9, pp. e1005834, (2016) (PubMed).
Bolstad, Abaitua, Crump, OHare: "Autocatalytic activity of the ubiquitin-specific protease domain of herpes simplex virus 1 VP1-2." in: Journal of virology, Vol. 85, Issue 17, pp. 8738-51, (2011) (PubMed).
Shen, Sa e Silva, Jaber, Vitvitskaia, Li, Henderson, Jones: "Two small RNAs encoded within the first 1.5 kilobases of the herpes simplex virus type 1 latency-associated transcript can inhibit productive infection and cooperate to inhibit apoptosis." in: Journal of virology, Vol. 83, Issue 18, pp. 9131-9, (2009) (PubMed).
Satoh, Arii, Suenaga, Wang, Kogure, Uehori, Arase, Shiratori, Tanaka, Kawaguchi, Spear, Lanier, Arase: "PILRalpha is a herpes simplex virus-1 entry coreceptor that associates with glycoprotein B." in: Cell, Vol. 132, Issue 6, pp. 935-44, (2008) (PubMed).
Target
HSV1 ICP4
(Herpes Simplex Virus Type 1 ICP4 (HSV1 ICP4))